Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inozyme Pharma Inc | INZY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.39 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 2.689 - 7.5599 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 7.39 | USD |
Inozyme Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
456.49M | 61.77M | - | 0 | -67.06M | -1.09 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inozyme Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INZY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.05 | 7.5599 | 5.76 | 6.65 | 948,659 | 1.34 | 22.15% |
1 Month | 6.64 | 7.5599 | 5.46 | 6.22 | 696,251 | 0.75 | 11.30% |
3 Months | 4.19 | 7.5599 | 4.03 | 5.72 | 533,051 | 3.20 | 76.37% |
6 Months | 4.50 | 7.5599 | 2.689 | 4.75 | 472,488 | 2.89 | 64.22% |
1 Year | 3.65 | 7.5599 | 2.689 | 5.15 | 585,436 | 3.74 | 102.47% |
3 Years | 18.565 | 21.99 | 0.991 | 4.61 | 383,730 | -11.18 | -60.19% |
5 Years | 17.93 | 31.6499 | 0.991 | 5.35 | 326,203 | -10.54 | -58.78% |
Inozyme Pharma Description
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. |